Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Primary IgA Nephropathy
NCT04525729Phase 4Completed
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in IgA nephropathy (IgAN). Started Jul 2020; status: completed.
02
Drugs
rituximab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04525729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525729.